Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Microba Life Sciences Limited ( (AU:MAP) ).
Microba Life Sciences Limited announced a change in the director’s interest notice, with Richard Bund, a director of the company, disposing of 690,290 ordinary shares through SA Microba Holdings Pty Ltd. This transaction was part of the administration of a deceased estate and did not affect Bund’s personal holdings, indicating a procedural adjustment rather than a strategic shift in company operations.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.19 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
More about Microba Life Sciences Limited
Microba Life Sciences Limited operates in the life sciences industry, focusing on microbiome analysis and related services. The company provides advanced microbiome testing and analysis solutions, aiming to enhance health outcomes through a deeper understanding of gut health.
Average Trading Volume: 542,820
Technical Sentiment Signal: Sell
Current Market Cap: A$51.15M
For detailed information about MAP stock, go to TipRanks’ Stock Analysis page.